CMAJ April 13, 2004; 170 (8). doi:10.1503/cmaj.1031201.
© 2004 Canadian Medical Association or its licensors
All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.
Taking our vitamins
Ruth Wilson
Medical Student, Class of 2006, University of Western Ontario, London, Ont.
In Eric Wooltorton's article on vitamin and mineral supplements,1 a footnote to Table 1 states that vitamin K has an anticoagulant effect. In fact, vitamin K promotes healthy coagulation, because it is a cofactor in a carboxylation reaction that is essential for the clotting process.2 [A correction on this point was published previously.3Editor.]
Vitamin K was excluded from this table because it "is not available in Canadian multivitamin preparations."1 However, vitamin K is included in some multivitamins available in the United States. Given the popularity of cross-border shopping and the availability of products through the Internet, it is possible that many patients of CMAJ readers, or even the journal's readers themselves, are consuming vitamin K in supplement form.
Despite several trials evaluating vitamin K (vitamin K1 [phylloquinone] and vitamin K2 [menatetrenone]) for its effects on bone quality and density4,5,6 and its usefulness in other contexts,7 the toxic effects of even pharmaceutical doses of these 2 naturally occurring forms of vitamin K have not been identified.8 In addition, at least one study, which evaluated the effects of large doses of vitamin K2 (45 mg of menaquinone-4) on hemostatic activation, found no thrombotic tendency at high doses.9
Ruth Wilson Medical Student, Class of 2006 University of Western Ontario London, Ont.
References
- Wooltorton E. Too much of a good thing? Toxic effects of vitamin and mineral supplements. CMAJ 2003;169(1):47-8.[Free Full Text]
- Vermeer C, Schurgers LJ. A comprehensive review of vitamin K and vitamin K antagonists. Hematol Oncol Clin North Am 2000;14(2):339-52.[CrossRef][Medline]
- Corrections. CMAJ 2003;169(4):283.[Free Full Text]
- Iwamoto I, Kosha S, Noguchi S, Murakami M, Fujino T, Douchi T, et al. A longitudinal study of the effect of vitamin K2 on bone mineral density in postmenopausal women: a comparative study with vitamin D3 and estrogenprogestin therapy. Maturitas 1999;31(2):161-4. [CrossRef][Medline]
- Yonemura K, Kimura M, Miyaji T, Hishida A. Short-term effect of vitamin K administration on prednisolone-induced loss of bone mineral density in patients with chronic glomerulonephritis. Calcif Tissue Int 2000;66(2):123-8.[CrossRef][Medline]
- Somekawa Y, Chigughi M, Harada M, Ishibashi T. Use of vitamin K2 (menatetrenone) and 1,25-dihydroxyvitamin D3 in the prevention of bone loss induced by Leuprolide. J Clin Endocrinol Metab 1999;84(8):2700-4. [Abstract/Free Full Text]
- Takami A, Asakura H, Nakao S. Menatetrenone, a vitamin K2 analog, ameliorates cytopenia in patients with refractory anemia of myelodysplastic syndrome. Ann Hematol 2002;81(1):16-9.[CrossRef][Medline]
- Fairfield KM, Fletcher RH. Vitamins for chronic disease prevention in adults. JAMA 2002; 287(23):3116-26. [Abstract/Free Full Text]
- Asakura H, Myou S, Ontachi Y, Mizutani T, Kato M, Saito M, et al. Vitamin K administration to elderly patients with osteoporosis induces no hemostatic activation, even in those with suspected vitamin K deficiency. Osteoporos Int 2001; 12 (12):996-1000.[CrossRef][Medline]